Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma

In an open-label, multicenter phase II study of Japanese patients with cytokine-refractory metastatic renal cell carcinoma, axitinib showed substantial antitumor activity with an acceptable safety profile. Here, we report overall survival and updated efficacy and safety results. Sixty-four Japanese...

Descripción completa

Detalles Bibliográficos
Autores principales: Eto, Masatoshi, Uemura, Hirotsugu, Tomita, Yoshihiko, Kanayama, Hiroomi, Shinohara, Nobuo, Kamei, Yoichi, Fujii, Yosuke, Umeyama, Yoshiko, Ozono, Seiichiro, Naito, Seiji, Akaza, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317969/
https://www.ncbi.nlm.nih.gov/pubmed/25283266
http://dx.doi.org/10.1111/cas.12546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317969/
https://www.ncbi.nlm.nih.gov/pubmed/25283266
http://dx.doi.org/10.1111/cas.12546

Ejemplares similares